$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
帕博西林显著提高乳腺癌患者治疗率
2025-10-19 11:44:20
Check Details
卡培他滨可用于晚期乳腺癌维持治疗
2025-10-19 11:44:20
Check Details
帕博西林与内分泌疗法联合可对抗多种癌症
2025-10-19 11:44:20
Check Details
奥拉帕尼使BRCA突变的乳腺癌患者获益
2025-10-19 11:44:20
Check Details
依维莫司联合来曲唑治疗HER2阴性乳腺癌
2025-10-19 11:44:20
Check Details
尼拉帕尼治疗乳腺癌
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗三阴性乳腺癌
2025-10-19 11:44:20
Check Details
帕博西林联合来曲唑可延长乳腺癌患者生存期
2025-10-19 11:44:20
Check Details
帕博西尼联合来曲唑可明显延长乳腺癌患者生存期
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗BRCA1/2突变的晚期乳腺癌
2025-10-19 11:44:20
Check Details
帕博西尼在局部晚期,非炎性乳腺癌的治疗
2025-10-19 11:44:20
Check Details
帕博西尼在ER 阳性和(或)HER-2 阴性晚期乳腺癌的治疗
2025-10-19 11:44:20
Check Details
1
2
...
1657
1658
1659
1660
1661
1662
1663
...
4163
4164
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Anamorelin (ADLUMIZ): GHS-R1a Agonist for Cancer Cachexia—Mechanism, Use, and Safety Boundaries
2
Vemurafenib Mechanism and Clinical Indications: BRAF V600E Mutant Melanoma and ECD Treatment
3
Ribociclib: Mechanism of Action and Approved Uses in Breast Cancer
4
Binimetinib + Encorafenib: Dual MEK/BRAF Targeting in BRAF+ Tumors
5
Neratinib Dosing: 240mg Start, Diarrhea Prophylaxis, Hepatic Adjustment
6
Selumetinib and KRAS Mutations: Where the MEK Inhibitor Actually Fits
7
Erdafitinib in Lung Squamous Cell Carcinoma: Indication Boundaries and FGFR Interpretation
8
Daraxonrasib (Rasonque): Chemical Identity and RAS Tri-Complex Mechanism
9
Tamoxifen and Feeling Older: Managing Hot Flashes, Fatigue, and Skin Changes
10
FDA Approves Pembrolizumab for TMB-H Solid Tumors: Threshold ≥13 mut/Mb, KEYNOTE-158 Data
11
Capmatinib for METex14 NSCLC: Test First, Monitor Toxicity
12
Ribociclib Still Allows Recurrence: HR+/HER2- Adjuvant and Advanced Use